IN THE EXECUTION of any clinical trial for the treatment of cancer it is generally considered unethical and also very inefficient to wait until the results on all patients have been obtained before making any inferences about the effectiveness of treatments. In statistical parlance the "fixed sample size" approach is unacceptable. Nevertheless many trial protocols specify a fixed number of patients, often with certain statistical design objectives in mind, but one assumes from experience that the trial organizers do not intend to be as inflexible as they imply.
At the other extreme there exist methods of sequential design and analysis, as described in Armitage (1975) , which are geared to the idea that after every additional patient on each treatment has been evaluated, some formal statistical stopping rules are applied to determine whether the whole trial should stop. Such a sequential approach is likely to involve certain assumptions:
(1) the response variable conforms to some standard statistical distribution, (2) patients enter in matched pairs (one to each treatment); (3) patient evaluation is instantaneous; (4) constant surveillance is made of the accumulating data.
The situation for a typical cancer clinical trial is rather different:
(1) response is measured either by tumour shrinkage, disease-free interval or patient survival, any of which may have awkward distributions; (2) patients vary with respect to several prognostic factors, and although stratification can be a partial solution, pairing of patients is impractical; (3) responses such as those mentioned in (1) may take months or years to observe; moreover, patient entry from several hospitals will require a complex system of central data collection which entails some delay between patient evaluation at the hospital and inclusion of his outcome in the analysis; (4) the statistician and trial organizers will normally be too busy to maintain a constant vigil over the data in order to observe the point at which a sequential boundary is crossed.
Hence there is a sharp contrast between the theoretical ideal of sequential methods and the practical situation of cancer clinical trials. This is certainly my own experience, since I am unaware of any cancer clinical trial which has successfully implemented a formal sequential design.
Therefore neither fixed sample size nor conventional sequential methods are applicable. Instead the cancer clinical trial will normally proceed with some inspection of results from time to time with an informal interpretation by the trial organizers as to whether any action to stop or change a treatment is justified. Some fixed sample-size significance tests may be used to aid decision making, but the overall approach is subjective. One might take the defeatist standpoint that any more formalized approach to the design and analysis of trials is unrealistic. However, I think this is liable to result in a very unscientific approach to clinical trials, whereby the statistical validity of conclusions would remain uncertain.
What is needed is a method of statistical design and analysis which takes into account the fact that it is common practice to assess the accumulating results of an ongoing trial at several equally spaced times, each ofwhich might normally occur before a meeting of the trial organizers. This paper describes one such general type of group sequential design based on the repeated use of conventional significance testing.
However, before we go into the details of such an approach, we should consider the current status of clinical trial practice.
A SURVEY ON THE SIZE OF CANCER TRIALS
This survey was undertaken for the UICC Project on Controlled Therapeutic Trials by Pocock et al. (1978) . The main questions of the survey were:
(1) Do investigators determine the required size of trial in advance?
(2) How successful are they in accruing an adequate number of patients?
(3) Do they assess interim results while the trial is in progress, and do such analyses affect the eventual size of trial?
The sampling frame for the survey was the 334 trials registered with the UIJC information office from 1972 to mid-1975. A random sample of 50 trials was chosen, and a questionnaire sent to each principal investigator. Completed questionnaires were received from 40 (80%). Eighteen of these were in Western Europe, 17 in the United States and 5 elsewhere. Twentyeight of the trials accrued patients from more than one centre, and 17 of these had more than 20 participating centres. All trials were randomized, this being a condition for inclusion in the UICC register. Twenty-eight of the trials had just 2 randomized treatment groups. Twenty-six trials were for chemotherapy, which is probably a true reflection of current trial activity. The trials covered a wide range of tumour sites, including 9 for leukaemia.
The replies to the most relevant questions are presented in 3 sections:
In 34/40 cases (85%) the required number of patients was specified before the trial began. If one expects to take up a maximum of I 0 repeated looks at one's data during the course of a trial, then one might wish to adopt a significance level of P < 0-01 as the criterion for stopping the trial, since the chances of drawing a false conclusion that one treatment is superior is roughly equivalent to making a decision based on a single test at the level P < 0-0,5.
GROUP SEQUENTIAL ANALYSIS
This section describes how repeated significance testing of accumulating data can be formulated as a precise method of statistical analysis for clinical trials. Armitage (1975) describes several RST sequential designs based on significance testing after each pair of patients, one to each treatment. However, as mentioned in Section 1, this continual testing has both theoretical and practical difficulties. Instead we consider the group sequential approach, whereby significance tests are performed at longer equally spaced intervals. The results and methods described here are based on Pocock (1977) and further reference to the same general approach can be obtained from McPherson (1974 McPherson ( , 1977 .
First, we return to the problem that repeated significance tests increase the overall significance level, that is, the probability of at least one significant difference when the treatments are really the same. Table I shows the results for At each of the 5 times the response rates are compared using a x2 test without continuity correction, with the intention of stopping the trial if P < 0O0158, the nominal significance level obtained from Table II . The lack of continuity correction is necessary to avoid the repeated testing being unduly conservative (see Pocock, 1977 Table III . Remember that the required nominal significance levels for any choice of N are to be found in Table  II . Clearly, as the number of groups N increases, the number per group 2n decreases and the maximum number of patients 2ntN increases. This means that the larger is N for a given cx and /3, the longer the trial will take to complete if the null hypothesis of no treatment difference appears to be true. Table Ill shows that in this situation 2000 more patients will be needed for a design with N1 5 compared to a "onelook" trial (N 1).
However, this is compensated by the most important feature in a group sequential design, which is the extent to which it enables early termination of trial when the alternative hypothesis is true. This is indicated in the last column of Table III by the average sample size. Evidently the greatest reduction is achieved by using a An additional problem is the premature publication of results while a trial is still in progress, which has the more serious effect that the whole medical community may be prejudiced towards a particular conclusion before the full results are known. Such early public presentation took place in at least 7 of the 40 survey trials mentioned above.
CONCLUSIONS
(1) For most clinical trials in cancer, some form of informal ongoing analysis of results is undertaken, though conventional sequential methods are hardly ever used.
(2) This practice of periodically analysing the accumulating data can be formulated more precisely as a group sequential design, whereby stopping rules are based on repeated significance testing at equal intervals. There appears no great advantage in carrying out many repeated tests, both for statistical reasons and because of the effort involved. One sensible design would be to plan for no more than 10 repeated analyses, with a decision to stop the trial if the main treatment difference is significant at the I% level.
(3) Such statistical stopping rules can never be rigorously applied but should improve the objectivity of decisionmaking.
(4) Difficulties in obtaining adequate patient accrual, administrative inefficiency and premature dissemination of results are major faults in the organization of many cancer trials for which no amount of statistical refinement can correct.
I am grateful to Professor P. Armitage for helpful advice.
